PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
The exercise period for warrants of series TO 4 commences today
Today is the first day for the exercise of Phase Holographic Imaging PHI AB’s warrants of series TO 4 which were issued in connection with the preferential issue of units that the Company carried out during 2022. The period lasts until October 3, 2024.
PostNews: Press Release
The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share
PHI announces that the exercise price for warrants of series TO 4 has been set at SEK 4.63 per new share.
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 2 September 2024
Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on 2 September 2024. The following resolutions were passed at the meeting.
PostNews
BioStock: PHI’s CEO comments on the approved US listing
PHI has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
PostBlog Post
OTC Market Center in New York welcomes PHI
Our very own ‘big apple’ news — PHI’s shares (OTCQB:PHIXF) are now also trading on the US-OTCQB Market! Go and see some snapshots and our CEO Patrik speaking on this exciting new chapter.
PostNews: Press Release
PHI enters the US capital market – shares now also traded on OTCQB
PHI is thrilled to announce its official approval for also listing on the OTCQB Venture Market in the U.S., with trading commencing Thursday, August 15th. (OTCQB:PHIXF).
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI aims for US listing
BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
